Evaluation of a COVID-19 Vaccine Campaign and SARS-CoV-2 Infection and Mortality Among Adults Aged 60 Years And Older in a Middle-Income Country-Reference-Cited by-同舟云学术

Evaluation of a COVID-19 Vaccine Campaign and SARS-CoV-2 Infection and Mortality Among Adults Aged 60 Years And Older in a Middle-Income Country

Published:2021-10-29 Issue:10 Volume:4 Page:e2130800
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Macchia Alejandro¹,Ferrante Daniel¹,Angeleri Patricia¹,Biscayart Cristián¹,Mariani Javier²,Esteban Santiago³,Tablado Manuel Rodríguez³,de Quirós Fernán González Bernaldo⁴

Affiliation:

1. Subsecretaría de Planificación Sanitaria, Ministerio de Salud de la Ciudad de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina

2. Dirección General de Docencia, Investigación y Desarrollo Profesional, Ministerio de Salud de la Ciudad de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina

3. Gerencia Operativa de Gestión de Información y Estadísticas de Salud Dirección General de Sistemas de Información Sanitaria Subsecretaría de Planificación Sanitaria Ministerio de Salud, Ciudad Autónoma de Buenos Aires, Argentina

4. Minister of Public Health of the Autonomous City of Buenos Aires, Argentina

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2785597/macchia_2021_oi_210888_1634912419.69446.pdf

Reference11 articles.

1. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting.;Dagan;N Engl J Med,2021

2. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.;Haas;Lancet,2021

3. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on COVID-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study.;Lopez Bernal;BMJ,2021

4. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomized controlled phase 3 trial in Russia.;Logunov;Lancet,2021